264 related articles for article (PubMed ID: 25724527)
21. First-in-human study of E7130 (a tumor microenvironment-ameliorating microtubule inhibitor) in patients with advanced solid tumors: Primary results of the dose-escalation part.
Doi T; Matsubara N; Naito Y; Kuboki Y; Harano K; Ono M; Urasaki T; Ohmoto A; Kawanai T; Hisai T; Ikezawa H; Shiba S; Ito K; Semba T; Asano O; Takahashi S
Cancer; 2023 Aug; 129(15):2348-2359. PubMed ID: 37080942
[TBL] [Abstract][Full Text] [Related]
22. Dose escalation and expansion (phase Ia/Ib) study of GLS-010, a recombinant fully human antiprogrammed death-1 monoclonal antibody for advanced solid tumors or lymphoma.
Liu D; Ma C; Lu P; Gong J; Ye D; Wang S; Peng P; Bai Y; Song Y; Chen J; Jiang O; Zhang G; Ba Y; Chen L; Pan J; Li Q; Zhang L; Gu S; Yin X; Cao B; Han W; Dong H; Guo J; Zhang H; Su H; Jiang Y; Ouyang W; Ma L; Sun Y; Zhang F; Lv J; Guo Y; Xu C; Qi J; Wang L; Wang X; Liu Z; Shen L
Eur J Cancer; 2021 May; 148():1-13. PubMed ID: 33691262
[TBL] [Abstract][Full Text] [Related]
23. A phase 1 study of ramucirumab in Japanese patients with advanced solid tumors.
Nokihara H; Yamamoto N; Yamada Y; Honda K; Asahina H; Tamura Y; Hozak RR; Gao L; Suzukawa K; Enatsu S; Tamura T
Jpn J Clin Oncol; 2017 Apr; 47(4):298-305. PubMed ID: 28158463
[TBL] [Abstract][Full Text] [Related]
24. A phase 1a/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid tumors.
Falchook GS; Peeters M; Rottey S; Dirix LY; Obermannova R; Cohen JE; Perets R; Frommer RS; Bauer TM; Wang JS; Carvajal RD; Sabari J; Chapman S; Zhang W; Calderon B; Peterson DA
Invest New Drugs; 2021 Oct; 39(5):1284-1297. PubMed ID: 33852104
[TBL] [Abstract][Full Text] [Related]
25. A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer.
Rosen LS; Goldman JW; Algazi AP; Turner PK; Moser B; Hu T; Wang XA; Tuttle J; Wacheck V; Wooldridge JE; Banck M
Clin Cancer Res; 2017 Apr; 23(8):1910-1919. PubMed ID: 27803065
[No Abstract] [Full Text] [Related]
26. Phase 1 study of narnatumab, an anti-RON receptor monoclonal antibody, in patients with advanced solid tumors.
LoRusso PM; Gounder M; Jalal SI; André V; Kambhampati SRP; Loizos N; Hall J; Holzer TR; Nasir A; Cosaert J; Kauh J; Chiorean EG
Invest New Drugs; 2017 Aug; 35(4):442-450. PubMed ID: 28161886
[TBL] [Abstract][Full Text] [Related]
27. Phase I Study of DMOT4039A, an Antibody-Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer.
Weekes CD; Lamberts LE; Borad MJ; Voortman J; McWilliams RR; Diamond JR; de Vries EG; Verheul HM; Lieu CH; Kim GP; Wang Y; Scales SJ; Samineni D; Brunstein F; Choi Y; Maslyar DJ; Colon-Otero G
Mol Cancer Ther; 2016 Mar; 15(3):439-47. PubMed ID: 26823490
[TBL] [Abstract][Full Text] [Related]
28. Phase I study of MSB2311, a novel pH-dependent anti-PD-L1 monoclonal antibody, treating patients with advanced solid tumors and lymphoma.
Zhang Q; Zhang J; Zhong H; Yuan Y; Yang L; Zhang Q; Ji D; Gong J; Li J; Yao Z; Qi C; Wang J; Lu L; Shi M; Qian X; Shen L; Li J; Hu X
Cancer Immunol Immunother; 2023 Aug; 72(8):2729-2739. PubMed ID: 37115210
[TBL] [Abstract][Full Text] [Related]
29. A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors.
Naing A; Gainor JF; Gelderblom H; Forde PM; Butler MO; Lin CC; Sharma S; Ochoa de Olza M; Varga A; Taylor M; Schellens JHM; Wu H; Sun H; Silva AP; Faris J; Mataraza J; Cameron S; Bauer TM
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32179633
[TBL] [Abstract][Full Text] [Related]
30. Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study.
Shen L; Guo J; Zhang Q; Pan H; Yuan Y; Bai Y; Liu T; Zhou Q; Zhao J; Shu Y; Huang X; Wang S; Wang J; Zhou A; Ye D; Sun T; Gao Y; Yang S; Wang Z; Li J; Wu YL
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32561638
[TBL] [Abstract][Full Text] [Related]
31. Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor-related protein agonist AMG 228 in patients with advanced solid tumors.
Tran B; Carvajal RD; Marabelle A; Patel SP; LoRusso PM; Rasmussen E; Juan G; Upreti VV; Beers C; Ngarmchamnanrith G; Schöffski P
J Immunother Cancer; 2018 Sep; 6(1):93. PubMed ID: 30253804
[TBL] [Abstract][Full Text] [Related]
32. Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors.
Juric D; Dienstmann R; Cervantes A; Hidalgo M; Messersmith W; Blumenschein GR; Tabernero J; Roda D; Calles A; Jimeno A; Wang X; Bohórquez SS; Leddy C; Littman C; Kapp AV; Shames DS; Penuel E; Amler LC; Pirzkall A; Baselga J
Clin Cancer Res; 2015 Jun; 21(11):2462-70. PubMed ID: 26034219
[TBL] [Abstract][Full Text] [Related]
33. A first-in-human phase I study of the PD-1 inhibitor, retifanlimab (INCMGA00012), in patients with advanced solid tumors (POD1UM-101).
Lakhani N; Cosman R; Banerji U; Rasco D; Tomaszewska-Kiecana M; Garralda E; Kornacki D; Li J; Tian C; Bourayou N; Powderly J
ESMO Open; 2024 Apr; 9(4):102254. PubMed ID: 38387109
[TBL] [Abstract][Full Text] [Related]
34. First-in-human, phase I study of PF-06647263, an anti-EFNA4 calicheamicin antibody-drug conjugate, in patients with advanced solid tumors.
Garrido-Laguna I; Krop I; Burris HA; Hamilton E; Braiteh F; Weise AM; Abu-Khalaf M; Werner TL; Pirie-Shepherd S; Zopf CJ; Lakshminarayanan M; Holland JS; Baffa R; Hong DS
Int J Cancer; 2019 Oct; 145(7):1798-1808. PubMed ID: 30680712
[TBL] [Abstract][Full Text] [Related]
35. Phase I dose-finding study of monotherapy with atezolizumab, an engineered immunoglobulin monoclonal antibody targeting PD-L1, in Japanese patients with advanced solid tumors.
Mizugaki H; Yamamoto N; Murakami H; Kenmotsu H; Fujiwara Y; Ishida Y; Kawakami T; Takahashi T
Invest New Drugs; 2016 Oct; 34(5):596-603. PubMed ID: 27363843
[TBL] [Abstract][Full Text] [Related]
36. A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors.
Ferrarotto R; Eckhardt G; Patnaik A; LoRusso P; Faoro L; Heymach JV; Kapoun AM; Xu L; Munster P
Ann Oncol; 2018 Jul; 29(7):1561-1568. PubMed ID: 29726923
[TBL] [Abstract][Full Text] [Related]
37. A phase I monotherapy study of RG7212, a first-in-class monoclonal antibody targeting TWEAK signaling in patients with advanced cancers.
Lassen UN; Meulendijks D; Siu LL; Karanikas V; Mau-Sorensen M; Schellens JH; Jonker DJ; Hansen AR; Simcox ME; Schostack KJ; Bottino D; Zhong H; Roessler M; Vega-Harring SM; Jarutat T; Geho D; Wang K; DeMario M; Goss GD
Clin Cancer Res; 2015 Jan; 21(2):258-66. PubMed ID: 25388164
[TBL] [Abstract][Full Text] [Related]
38. Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial.
de Bono JS; Concin N; Hong DS; Thistlethwaite FC; Machiels JP; Arkenau HT; Plummer R; Jones RH; Nielsen D; Windfeld K; Ghatta S; Slomovitz BM; Spicer JF; Yachnin J; Ang JE; Mau-Sørensen PM; Forster MD; Collins D; Dean E; Rangwala RA; Lassen U
Lancet Oncol; 2019 Mar; 20(3):383-393. PubMed ID: 30745090
[TBL] [Abstract][Full Text] [Related]
39. LY3022855, an anti-colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation trial.
Dowlati A; Harvey RD; Carvajal RD; Hamid O; Klempner SJ; Kauh JSW; Peterson DA; Yu D; Chapman SC; Szpurka AM; Carlsen M; Quinlan T; Wesolowski R
Invest New Drugs; 2021 Aug; 39(4):1057-1071. PubMed ID: 33624233
[TBL] [Abstract][Full Text] [Related]
40. First-in-Human Study of AMG 820, a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody, in Patients with Advanced Solid Tumors.
Papadopoulos KP; Gluck L; Martin LP; Olszanski AJ; Tolcher AW; Ngarmchamnanrith G; Rasmussen E; Amore BM; Nagorsen D; Hill JS; Stephenson J
Clin Cancer Res; 2017 Oct; 23(19):5703-5710. PubMed ID: 28655795
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
